SISumit Isharwal

Sumit Isharwal

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Sumit Isharwal has a total of 16 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Valproic acid causes dose- and time-dependent changes in nuclear structure in prostate cancer cellsin vitroandin vivo

    by Madeleine S.Q. Kortenhorst, Sumit Isharwal, Paul J. van Diest, Wasim H. Chowdhury, Cameron Marlow, Michael A. Carducci, Ronald Rodriguez, Robert W. Veltri

    Histone deacetylase inhibitors such as valproic acid (VPA) are promising anticancer agents that change the acetylation status of histones and loosen the chromatin structure. We assessed nuclear structure changes induced by VPA in prostate cancer LNCaP, CWR22R, DU145, and PC3 cell lines and xenografts and their potential use as a biomarker of treatment. In vitro tissue microarrays consisted of prostate cancer cell lines treated for 3, 7, or 14 days with 0, 0.6, or 1.2 mmol/L VPA. In vivo tissue microarrays consisted of cores from prostate cancer xenografts from nude mice treated for 30 days with 0.2% or 0.4% VPA in drinking water. Digital images of at least 200 Feulgen DNA-stained nuclei were captured using the Nikon CoolScope and nuclear alterations were measured. With a set of seven most frequently significant nuclear alterations (determined by univariate logistic regression analysis), control and VPA treatment nuclei were compared in vitro and in vivo. Depending on the cell line, area under the curve-receiver operating characteristics ranged between 0.6 and 0.9 and were dose- and time-dependent both in vitro and in vivo. Also, VPA treatment caused significant nuclear alterations in normal drug-filtering organs (liver and kidney tissue). In vitro and in vivo VPA treatment of prostate cancer cell lines results in significant dose- and time-dependent changes in nuclear structure. Further, VPA induces nuclear structural changes in normal liver and kidney tissue, which likely reflects a natural physiologic response. Therefore, nuclear structural alterations may serve as a biomarker for histone deacetylase inhibitor treatment. [Mol Cancer Ther 2009;8(4):802–8]


  • Long‐Term assessment of prostate cancer progression free survival: Evaluation of pathological parameters, nuclear shape and molecular biomarkers of pathogenesis

    by Robert W. Veltri, Sumit Isharwal, M. Craig Miller, Jonathan I. Epstein, Leslie A. Mangold, Elizabeth Humphreys, Alan W. Partin

    Background Molecular pathways of proliferation, angiogenesis, neuroendocrine differentiation, apoptosis and alterations in nuclear structure of cancer epithelial cells are important in the pathogenesis of prostate cancer (PCa). Therefore, we evaluated the prognostic value of these parameters in 105 clinically localized PCa tumors with long‐term follow‐up after radical prostatectomy for progression‐free survival (PFS). Method Nuclear roundness variance (NRV) was calculated for tumor nuclei using the graphic tracing DynaCELL system. Immunohistochemistry assessed expression of Ki67, PCNA (proliferation), Chromogranin A (neuroendocrine differentiation), CD31 (angiogenesis), BCL2 (apoptosis), and Her‐2/neu (oncogene) in the tumors. Cox proportional hazards regression, Spearman's rank correlation, and Kaplan–Meier plots were employed to analyze the data. Results Gleason score, focal vs. non‐focal extra‐prostatic extension, organ confined status, NRV, Her‐2/neu, CD‐31 and Ki67 were univariately significant predictors of PFS. NRV was the most significant prognostic indicator with the highest concordance index (0.7) for PFS. Gleason score, NRV and Her‐2/neu were multivariately significant and yielded a concordance index of 0.77. Conclusion Her‐2/neu oncogene and NRV were shown to be significant in the prediction of PFS. The assessment of alterations in nuclear structure using NRV proved to be the most significant factor in the prediction of PFS. Integration of image analysis‐based NRV and molecular biomarkers with pathologic parameters should be considered for validation in the prediction of PFS. Prostate


  • Open Access

    Prognostic value of Her‐2/neu and DNA index for progression, metastasis and prostate cancer‐specific death in men with long‐term follow‐up after radical prostatectomy

    by Sumit Isharwal, Michael Craig Miller, Jonathan I. Epstein, Leslie A. Mangold, Elizabeth Humphreys, Alan W. Partin, Robert W. Veltri

    Abnormal DNA content in tumor cells represents large scale chromosomal alterations and reflects later changes of genetic instability. Her‐2/neu oncogene is amplified in 20–30% of breast and ovarian cancer patients and is associated with poor prognosis. Therefore, we evaluated prognostic value of Her‐2/neu expression and DNA content measurements in 252 clinically localized PCa patients with long‐term follow‐up after radical prostatectomy for progression, metastasis and PCa‐specific death. Her‐2/neu expression was determined by immunohistochemistry and DNA content measurements employed Feulgen‐stained cancer nuclei captured using static image cytometry system. Cox proportional hazard regression and Kaplan‐Meir plots were used to identify significant prognostic factors for progression, metastasis and PCa‐specific death. The proportions of Her‐2/neu positive and high %DNA index tumors significantly increased from nonprogressor to progressors without metastasis to progressors with metastasis (p < 0.0001; p = 0.027; p ≤ 0.001), metastasis (p ≤ 0.01) PCa‐specific death (p ≤ 0.04) in univariate analyses. Multivariately, Her‐2/neu expression and %DNA index were also significant for progression (p = 0.001), metastasis (p = 0.001) and PCa‐specific death (p = 0.02). When all other clinicopathologic information is available, the increment in concordance index by addition of either Her‐2/neu or DNA index was ∼2% and of both biomarkers was ∼3% for progression, metastasis and PCa‐specific death free survival models. Therefore, patients with Her‐2/neu positive and high %DNA index are at a higher risk for disease progression, metastasis and PCa‐specific death. Further, Her‐2/neu expression and %DNA index may be used with clinicopathologic parameters for prediction of long‐term prognosis in PCa.


  • p300 (histone acetyltransferase) biomarker predicts prostate cancer biochemical recurrence and correlates with changes in epithelia nuclear size and shape

    by Sumit Isharwal, Michael C. Miller, Cameron Marlow, Danil V. Makarov, Alan W. Partin, Robert W. Veltri

    BACKGROUND: p300 impacts the transcription of several genes involved in key pathways critical to PCa progression. Therefore, we evaluated the prognostic value of p300 expression and its correlation with nuclear alterations seen in tumor cells in men with long‐term follow‐up after radical prostatectomy (RP).METHODS: NCI Cooperative Prostate Cancer Tissue Resource tissue microarray cores of 92 RP cases (56 non‐recurrences and 36 PSA recurrences) were utilized for the study. p300 expression was assessed by quantitative immunohistochemistry and nuclear alterations in Feulgen‐stained nuclei were evaluated by digital image analysis using the AutoCyte™ Pathology Workstation. Cox proportional hazards regression, Spearman's rank correlation, and Kaplan–Meier plots were employed to analyze the data.RESULTS: p300 expression significantly correlated with nuclear alterations seen in tumor cells; specifically with circular form factor (P = 0.012) and minimum feret (P = 0.048). p300 expression in high grade tumors (Gleason score ≥7) was significantly higher compared to low grade tumors (Gleason score 24% showed the highest risk for PCa biochemical recurrence (P = 0.002).CONCLUSIONS: p300 expression correlates with nuclear alterations seen in tumor cells and has prognostic value in predicting long‐term PCa biochemical recurrence‐free survival. Prostate 68:1097–1104, 2008.